annual cash & cash equivalents:
$115.85M-$2.52M(-2.13%)Summary
- As of today (June 22, 2025), HALO annual cash & cash equivalents is $115.85 million, with the most recent change of -$2.52 million (-2.13%) on December 31, 2024.
- During the last 3 years, HALO annual cash & cash equivalents has fallen by -$2.87 million (-2.42%).
- HALO annual cash & cash equivalents is now -50.53% below its all-time high of $234.19 million, reached on December 31, 2022.
Performance
HALO Cash and cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly cash & cash equivalents:
$176.33M+$60.48M(+52.20%)Summary
- As of today (June 22, 2025), HALO quarterly cash & cash equivalents is $176.33 million, with the most recent change of +$60.48 million (+52.20%) on March 31, 2025.
- Over the past year, HALO quarterly cash & cash equivalents has increased by +$11.70 million (+7.11%).
- HALO quarterly cash & cash equivalents is now -64.70% below its all-time high of $499.45 million, reached on March 31, 2021.
Performance
HALO quarterly cash & cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash and cash equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
HALO Cash and cash equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -2.1% | +7.1% |
| 3 y3 years | -2.4% | +49.6% |
| 5 y5 years | -3.6% | +68.2% |
HALO Cash and cash equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -50.5% | at low | -35.7% | +93.9% |
| 5 y | 5-year | -50.5% | at low | -64.7% | +168.2% |
| alltime | all time | -50.5% | >+9999.0% | -64.7% | >+9999.0% |
HALO Cash and cash equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2025 | - | $176.33M(+52.2%) |
| Dec 2024 | $115.85M(-2.1%) | $115.85M(-24.9%) |
| Sep 2024 | - | $154.32M(-17.9%) |
| Jun 2024 | - | $187.86M(+14.1%) |
| Mar 2024 | - | $164.63M(+39.1%) |
| Dec 2023 | $118.37M(-49.5%) | $118.37M(-56.8%) |
| Sep 2023 | - | $274.23M(+24.0%) |
| Jun 2023 | - | $221.16M(+129.5%) |
| Mar 2023 | - | $96.38M(-58.8%) |
| Dec 2022 | $234.19M(+97.3%) | $234.19M(+59.1%) |
| Sep 2022 | - | $147.16M(+61.8%) |
| Jun 2022 | - | $90.93M(-22.8%) |
| Mar 2022 | - | $117.83M(-0.7%) |
| Dec 2021 | $118.72M(-19.6%) | $118.72M(-75.9%) |
| Sep 2021 | - | $491.68M(+10.0%) |
| Jun 2021 | - | $446.97M(-10.5%) |
| Mar 2021 | - | $499.45M(+238.1%) |
| Dec 2020 | $147.70M(+22.9%) | $147.70M(+124.7%) |
| Sep 2020 | - | $65.74M(-50.8%) |
| Jun 2020 | - | $133.61M(+27.5%) |
| Mar 2020 | - | $104.82M(-12.8%) |
| Dec 2019 | $120.18M(+107.4%) | $120.18M(+103.0%) |
| Sep 2019 | - | $59.20M(-11.7%) |
| Jun 2019 | - | $67.04M(+10.6%) |
| Mar 2019 | - | $60.59M(+4.6%) |
| Dec 2018 | $57.94M(-65.7%) | $57.94M(+5.3%) |
| Sep 2018 | - | $55.02M(-0.3%) |
| Jun 2018 | - | $55.17M(-43.7%) |
| Mar 2018 | - | $98.01M(-41.9%) |
| Dec 2017 | $168.74M(+152.7%) | $168.74M(+2.6%) |
| Sep 2017 | - | $164.40M(+43.3%) |
| Jun 2017 | - | $114.75M(+153.9%) |
| Mar 2017 | - | $45.19M(-32.3%) |
| Dec 2016 | $66.76M(+54.2%) | $66.76M(+9.1%) |
| Sep 2016 | - | $61.21M(-0.0%) |
| Jun 2016 | - | $61.23M(-11.4%) |
| Mar 2016 | - | $69.09M(+59.6%) |
| Dec 2015 | $43.29M(-29.5%) | $43.29M(-39.5%) |
| Sep 2015 | - | $71.51M(+5.5%) |
| Jun 2015 | - | $67.77M(+53.0%) |
| Mar 2015 | - | $44.29M(-27.9%) |
| Dec 2014 | $61.39M(+124.4%) | $61.39M(+32.4%) |
| Sep 2014 | - | $46.38M(-17.4%) |
| Jun 2014 | - | $56.13M(-26.7%) |
| Mar 2014 | - | $76.57M(+179.9%) |
| Dec 2013 | $27.36M | $27.36M(+56.4%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2013 | - | $17.49M(-37.4%) |
| Jun 2013 | - | $27.93M(-28.4%) |
| Mar 2013 | - | $39.02M(-60.8%) |
| Dec 2012 | $99.50M(+88.4%) | $99.50M(+13.6%) |
| Sep 2012 | - | $87.61M(-14.1%) |
| Jun 2012 | - | $102.04M(-12.5%) |
| Mar 2012 | - | $116.61M(+120.7%) |
| Dec 2011 | $52.83M(-36.6%) | $52.83M(-20.4%) |
| Sep 2011 | - | $66.33M(-16.2%) |
| Jun 2011 | - | $79.12M(+7.2%) |
| Mar 2011 | - | $73.83M(-11.3%) |
| Dec 2010 | $83.26M(+23.4%) | $83.26M(-7.3%) |
| Sep 2010 | - | $89.84M(+117.5%) |
| Jun 2010 | - | $41.31M(-25.1%) |
| Mar 2010 | - | $55.18M(-18.2%) |
| Dec 2009 | $67.46M(+5.9%) | $67.46M(-13.1%) |
| Sep 2009 | - | $77.64M(-13.0%) |
| Jun 2009 | - | $89.24M(+43.8%) |
| Mar 2009 | - | $62.07M(-2.6%) |
| Dec 2008 | $63.72M(-34.8%) | $63.72M(-12.1%) |
| Sep 2008 | - | $72.49M(-12.0%) |
| Jun 2008 | - | $82.41M(-11.0%) |
| Mar 2008 | - | $92.56M(-5.2%) |
| Dec 2007 | $97.68M(+121.0%) | $97.68M(-7.1%) |
| Sep 2007 | - | $105.11M(+4.5%) |
| Jun 2007 | - | $100.60M(+41.7%) |
| Mar 2007 | - | $70.97M(+60.6%) |
| Dec 2006 | $44.19M(+131.0%) | $44.19M(+174.5%) |
| Sep 2006 | - | $16.10M(+6.6%) |
| Jun 2006 | - | $15.10M(-14.1%) |
| Mar 2006 | - | $17.57M(-8.2%) |
| Dec 2005 | $19.13M(+19.5%) | $19.13M(+188.3%) |
| Sep 2005 | - | $6.64M(-34.0%) |
| Jun 2005 | - | $10.06M(-23.4%) |
| Mar 2005 | - | $13.13M(-18.0%) |
| Dec 2004 | $16.01M(+3078.7%) | $16.01M(+360.0%) |
| Sep 2004 | - | $3.48M(-41.4%) |
| Jun 2004 | - | $5.94M(-20.3%) |
| Mar 2004 | - | $7.45M(+1379.9%) |
| Dec 2003 | $503.60K(+1829.5%) | $503.60K(+704.5%) |
| Sep 2003 | - | $62.60K(-9.7%) |
| Jun 2003 | - | $69.30K(-5.2%) |
| Mar 2003 | - | $73.10K(-34.6%) |
| Sep 2002 | - | $111.80K(-8.6%) |
| Jun 2002 | - | $122.30K(+805.9%) |
| Mar 2002 | - | $13.50K |
| Dec 2001 | $26.10K | - |
FAQ
- What is Halozyme Therapeutics annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Halozyme Therapeutics?
- What is Halozyme Therapeutics annual cash & cash equivalents year-on-year change?
- What is Halozyme Therapeutics quarterly cash & cash equivalents?
- What is the all time high quarterly cash & cash equivalents for Halozyme Therapeutics?
- What is Halozyme Therapeutics quarterly cash & cash equivalents year-on-year change?
What is Halozyme Therapeutics annual cash & cash equivalents?
The current annual cash & cash equivalents of HALO is $115.85M
What is the all time high annual cash & cash equivalents for Halozyme Therapeutics?
Halozyme Therapeutics all-time high annual cash & cash equivalents is $234.19M
What is Halozyme Therapeutics annual cash & cash equivalents year-on-year change?
Over the past year, HALO annual cash & cash equivalents has changed by -$2.52M (-2.13%)
What is Halozyme Therapeutics quarterly cash & cash equivalents?
The current quarterly cash & cash equivalents of HALO is $176.33M
What is the all time high quarterly cash & cash equivalents for Halozyme Therapeutics?
Halozyme Therapeutics all-time high quarterly cash & cash equivalents is $499.45M
What is Halozyme Therapeutics quarterly cash & cash equivalents year-on-year change?
Over the past year, HALO quarterly cash & cash equivalents has changed by +$11.70M (+7.11%)